August 17, 2006 – According to Forbes, a drug from Roche that boosts HDL, the good cholesterol, may be more effective than torcetrapib, the highly anticipated, widely publicized compound from Pfizer that expects to contend in the same space. The two drugs share the same mechanism, and early tests showed the Pfizer drug to be much more effective. But a small change in the administration of the Roche drug may change all that...
